- Enzyme Replacement Therapy
- Gene Therapy
Pompe Disease Drug Sales was valued at USD 1.2 billion in 2022 and projected to reach USD 1.8 billion by 2027, at a CAGR of 8% from 2023-29. Pompe illness is a genetic metabolic ailment that affects babies and is caused by mutations in the GAA gene, which produces the acid alpha-glucosidase enzyme, which reduces glycogen to a simple form. The lack or mutation of the GAA gene causes glycogen buildup, which causes heart problems, muscle weakness, and liver damage, which can lead to early death.
How will Maze Therapeutics deal benefit the Sanofi?
Pompe Disease Treatment Market Key Developments:
Fastest Growing Market
Growing incidence of the pompe disease globally projected to drive the sales of the pompe disease therapeutics over the forecast period. According to a research study, approximately 5,000 to 10,000 people are affected with pompe disease around the world. Moreover, according to National Organization for Rare Disorders, pompe disease incidence is generally placed at approximately 1 in 40,000 births in the United States
The global pompe disease treatment market size was valued at USD 1.2 billion in 2022
Actus Therapeutics, Inc., BioMarin Pharmaceutical, Audentes Therapeutics, Amicus Therapeutics, Sanofi Genozyme, Greenovation Biotech GmbH, Valerion Therapeutics
North America has the highest growth rate